Shree Pushkar Chemicals & Fertilizers Ltd Q1 FY27 Earnings Analysis

Published 27 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹1.3K Cr

Price

365

Market Cap

₹1.3K Cr

P/E Ratio

17.1

Revenue Rank

Rank 3

Margin Rank

Rank 3

Earnings Summary

- Company expects revenue around Rs. - Shree Pushkar expects steady growth supported by higher volumes in chemicals and improved fertilizer realizations, as reflected in FY26 performance (21% revenue growth, 18.7% EBITDA growth).

📊 Revenue & Sales Performance

Rank 3

- Company expects revenue around Rs. 1,250 - 1,300 crores for FY27, factoring in older volumes and pricing without additional volume impact currently. - Utilization expected to be stable at 65-70% for Q1 and Q2, with Unit 5 and Unit 6 commercialization potentially starting in Q1 or Q2 post-Kharif season. - Delayed start of Unit 5 and 6 due to raw material supply and pricing issues; trials can begin within a month once conditions stabilize. - Management foresees better profitability in upcoming quarters due to liquidation of held inventories at higher prices. - Future volumes linked to seasonal patterns (Kharif and Rabi); cautious about immediate volume growth due to market uncertainties. - A significant capex of Rs. 350 crores planned for expansion at Madhya Bharat, possibly funded through internal accruals and limited term loans. - Overall tone is conservative and realistic considering current market volatility.

📈 Profitability & Margins

Rank 3

- Shree Pushkar expects steady growth supported by higher volumes in chemicals and improved fertilizer realizations, as reflected in FY26 performance (21% revenue growth, 18.7% EBITDA growth). - The company aims to maintain or improve capacity utilization (~65-70%) and market share without decline, supporting stable profits. - Expansion initiatives, particularly Unit 5 and Unit 6, are near completion and ready for commercialization; trials can start within a month when market conditions stabilize. - The company is cautious on near-term raw material price volatility and global logistics but views it as an opportunity to reset price realizations at higher levels. - Taxation is expected at 22-25%, with Pushkar possibly at 18% due to carry-forward MAT benefits, impacting net profitability estimates. - The company is debt-light, funding capex largely through internal accruals, supporting sustained financial discipline and growth. - Management expects Q1 FY27 performance to improve over past quarters, viewing market stabilization and inventory liquidation positively for profitability expansion.

🏗️ Capital Expenditure Plans

Yes

- Completed a capex of Rs. 174 crores in FY24, including Madhya Bharat acquisition and Unit 5 build-up, fully funded by internal accruals. - Ongoing capex of Rs. 155 crores for Unit 5 dyes unit, solar project (Rs. 35 crores), and Unit 6 (Rs. 85 crores). Funded mostly by internal accruals; Rs. 25 crores term loan taken for solar project. - Planned future capex of Rs. 350 crores for additional facility at Madhya Bharat Phosphates, partly funded by Rs. 140 crores in AAA-rated bonds and Rs. 30 crores preferential allotment to the promoter. - Balance Rs. 180 crores funding undecided; likely mix of internal accruals and up to 25-30% term loan. - Emphasis on debt-free capex funded largely internally, supporting expansion with minimal financial pressure. - Expansion projects (Unit 5 and 6) paused due to raw material pricing challenges, but ready for commercialization within a month when market conditions improve.

💰 Fundraising & Capital Structure

Yes

- The company has planned a capex of around Rs. 320-350 crores, majorly funded through internal accruals. - For the Rs. 155 crores capex (Unit 5 dyes unit, solar project, Unit 6), only a Rs. 25 crore term loan has been taken for the solar project from HDFC Bank; the rest is from internal funds. - For the larger Rs. 350 crore capex at Madhya Bharat Phosphates, the company currently holds investments of around Rs. 140 crores plus Rs. 30 crores preferential allotment to promoters, totaling ~Rs. 170 crores. - The balance ~Rs. 180 crores for this capex may be funded either through 2 years of revenue or by taking some term loan (expected to be around 25-30% of the capex). - No major equity fundraising has been indicated; the company emphasizes funding primarily from internal accruals and limited debt. - The company is currently debt-free except for the Rs. 25 crore solar term loan.

📋 Order Book & Pipeline

No information

The transcript from page 11 of the document "1273007.pdf" does not provide specific information regarding the current or expected order book or pending orders for Shree Pushkar Chemicals & Fertilisers Limited. The discussion mainly focuses on: - Impact of the new Labour Code on the company's books. - Raw material price increases and their impact on margins. - Plant utilization rates and operational outlook. - Market conditions in Bangladesh post-elections. - Capital expenditure plans and funding. - Challenges with raw material availability and pricing (ammonia, sulphur). - Delay in commencement of new units (Unit 5 and 6) due to raw material price volatility. No explicit data about the orderbook or pending orders is mentioned in the provided pages.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

Yes

Order Book

No information

Frequently Asked Questions

What were Shree Pushkar Chemicals & Fertilizers Ltd Q1 FY27 results?

- Company expects revenue around Rs. - Shree Pushkar expects steady growth supported by higher volumes in chemicals and improved fertilizer realizations, as reflected in FY26 performance (21% revenue growth, 18.7% EBITDA growth).

What is Shree Pushkar Chemicals & Fertilizers Ltd share price analysis?

Shree Pushkar Chemicals & Fertilizers Ltd currently shows a below-average growth signal. The stock trades at a P/E of 17.1 with a market cap of ₹1,263. Investors should review the full earnings analysis for detailed insights.

Is Shree Pushkar Chemicals & Fertilizers Ltd planning capital expenditure?

- Completed a capex of Rs.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.